GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer

SEOUL, South Korea, March 20, 2026 /PRNewswire/ -- GI Innovation announced on 19th that it has entered into a clinical supply agreement with Johnson & Johnson to evaluate a combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a phase 1b clinical trial.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.